DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

Although DNA methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine, are used extensively in the treatment of myelodysplastic syndromes and acute myeloid leukemia, there remain unanswered questions about DNMTi's mechanism of action and predictors of clinical response. Because...

Descripción completa

Detalles Bibliográficos
Autores principales: Kagan, Amanda B., Garrison, Dominique A., Anders, Nicole M., Webster, Jonathan A., Baker, Sharyn D., Yegnasubramanian, Srinivasan, Rudek, Michelle A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432879/
https://www.ncbi.nlm.nih.gov/pubmed/37345219
http://dx.doi.org/10.1111/cts.13548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432879/
https://www.ncbi.nlm.nih.gov/pubmed/37345219
http://dx.doi.org/10.1111/cts.13548

Ejemplares similares